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Abstract
The Ku heterodimer, Ku70 and Ku80, plays a key role in DNA repair. Viable Ku70
knockouts exist in mice but not in human cell lines. The objective was to create Ku70
knockouts and evaluate knockout viability in human cells using CRISPR/Cas9 and TevCas9.
Editing is achieved by Cas9 through one sequence-specific blunt cut accompanied by errorprone DNA repair. However, TevCas9, a novel fusion protein of Cas9 and I-Tev, creates two
non-compatible DNA breaks and biases editing events towards a small deletion. Ku70 has five
processed pseudogenes therefore intron-exon junctions were targeted by gRNA and a cell line
stably transfected with an inducible second copy of Ku70-HA was used to compensate for the
loss of endogenous Ku70. After transfection with Cas9 or TevCas9, monoclonal cell lines were
picked. Analysis showed lowered or absent Ku70 expression. These Ku knockouts can be used
to determine if Ku is required for human cell viability.
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Summary for Lay Audience
The Ku protein, composed of two smaller proteins, Ku70 and Ku80, is important for
maintaining the integrity of DNA, through its function in DNA repair. There may be additional
functions for Ku in human cells as previous studies have reported that deleting Ku from human
cells caused cell death suggesting that Ku is essential in human cells. The goal of this project
is to generate a knockout cell that does not contain Ku70 to further study the role of Ku and to
evaluate whether removing Ku70 will kill human cells or not. CRISPR/Cas9 is a popular tool
used to remove a protein of interest from cells and gather knowledge on the protein by seeing
the effect of removing it on the cell. TevCas9 is a variation of Cas9 that may be more effective
and precise. We wanted to compare the efficiencies of Cas9 and TevCas9. Initially, trying to
knockout Ku70 in immortalized human cells was unsuccessful. To test whether this meant
Ku70 was essential or CRISPR-Cas9 was non-functional, we created a cell line with a second
copy of the Ku70 that can be turned on and off when needed. If removing Ku70 is lethal, the
second copy will produce some Ku70 protein that will keep the cell alive. This will allow the
first copy to be safely removed by CRISPR without killing the cells. Subsequently, we will
turn off the second copy too and observe whether cells can survive in the complete absence of
Ku70. The generation of these cells will serve as the basis for studies investigating other roles
of Ku outside well-known DNA repair and whether Ku has essential functions in human cells.
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Chapter 1

1

Introduction

1.1

DNA Damage

Cells are continuously at risk of deoxyribonucleic acid (DNA) damage by exogenous and
endogenous agents. For instance, on average, cell genomes are targets of tens of
thousands of lesions daily (1). Lesions can be caused by exogenous environmental agents
such as ultraviolet light, ionizing radiation (IR) and chemicals, including tobacco smoke
and aflatoxins (2). People are exposed to natural radiation sources on a daily basis (3) and
these naturally occurring environmental factors, such as IR, are difficult to avoid. Even in
the absence of exogenous factors, DNA damage can also occur through endogenous
agents such as dysfunctional topoisomerase I and II activity during DNA replication,
reactive oxygen species (ROS), a by-product of the electron transport chain, and reactive
nitrogen compounds, produced in immune cells as a response to inflammation (2, 4, 5).
Although DNA damage is common, if left unrepaired or repaired incorrectly, it can lead
to mutations in the genome that may be passed on to progeny or disrupt vital cellular
function such as DNA replication (2). Thus, the cell has acquired several DNA repair
responses to combat various forms of DNA lesions. Genetic defects in these DNA repair
responses are linked to mutagenesis, immunodeficiency, and malignancy, highlighting
their importance in genome stability (6).
While cell responses to DNA damage are specific to the type of lesion, all these pathways
follow a similar general scheme which relies on DNA damage sensors to correctly detect
lesions, followed by signalling cascades and activity of repair factors (2). Some specific
forms of lesions can be repaired by direct enzyme-mediated reversal, namely,
photolyase-, alkyltransferase-, and dioxygenase-mediated repair processes (7); however,
most are repaired by pathways with multiple sequential steps. Common forms of DNA
damage are base lesions, protein-DNA crosslinks, interstrand crosslinks and singlestranded DNA breaks. These lesions are effectively repaired by a multitude of pathways:
base-excision repair, mismatch repair, single-stranded break repair and nucleotide

2

excision repair (8–10). The majority of these repair processes include nucleases to resect
damaged DNA ends, polymerases to close the gaps, and ligases to rejoin the DNA
backbone (3). In some cases, lesions persist despite these repair mechanisms and can
block DNA replication. To avoid deadly stalling of the replication fork, error-prone and
low fidelity translesion DNA polymerases are used to bypass the lesion site (11).

1.2

Double-Stranded Break Repair

A less common but highly cytotoxic type of DNA damage is a double-stranded break
(DSB), where there is a simultaneous break in the sugar-phosphate backbones of two
complementary DNA strands. They must be repaired immediately to preserve
chromosomal integrity. If left unrepaired, DSBs can lead to DNA loss and deadly
chromosomal translocations. While most forms of DSBs are pathological, there are
physiological cell processes that rely on controlled creation and repair of DSBs. DSBs
play an important function in V(D)J recombination, the process responsible for creating
diversity in variable regions of immunoglobulins and T cell receptors (12).
Topoisomerase II relies on DSBs to control the supercoiled state of DNA (13) and
DSBs are required during recombination during gamete formation, specifically for the
resolution of the Holliday junction that forms during crossover events in prophase I
during meiosis (14). Pathological forms of DSBs are caused most frequently during DNA
replication when DNA is unwound and vulnerable. The majority of spontaneous DSBs
occur by replication across a nicked chromatid during S phase, creating a chromatid
break (15). The second most prevalent cause of DSBs is ROS followed by IR, and then
by mechanical stress on chromosomes (3).
The cell has two principal mechanisms of DNA repair to address DSBs. In replicating
organisms in the S phase, including replicating bacteria and replicating haploid yeast,
homology-directed repair (HDR) is the favoured option (3), namely homologous
recombination (HR) and single-strand annealing. All forms of HDR use the
complementarity of the sister chromatid to faithfully repair the DSB (16, 17).
In cases of DSBs in non-replicating haploid organisms and diploid organisms outside of
the S and G2 phase, homologous DNA is not available nearby to function as a template.
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For these situations, cells acquired another form of DSB repair early in evolution, called
non-homologous end joining (NHEJ) (11). The remarkable aspect of NHEJ is its ability
to recognize and join ends together with a wide range of overhang length, DNA end
sequence, and DNA end chemistry (3). Similar to most DNA repair pathways, NHEJ
pathways consist of a DSB sensor, nucleases, polymerases and ligases (18).

1.3

The Ku Heterodimer

At the beginning of NHEJ, the first protein to be recruited to the DSB is the Ku
heterodimer (Figure 1.1). It is a DNA binding protein, comprised of two subunits, Ku70
(X-ray cross complementing protein 6 [XRCC6]) and Ku80 (X-ray cross complementing
protein 5 [XRCC5]) (17). Ku70 and Ku80 appear to be obligate heterodimers. This is
supported by previous mouse knockout studies that found the knockout of either subunit
in Ku results in a drop in abundance of the other to negligible levels, suggesting subunit
dimerization may have a stabilizing effect (19, 20). Overall, the knockout of either Ku70
or Ku80 leads to functional knockout of the Ku heterodimer.
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Figure 1.1: Schematic representation of non-homologous end joining. The Ku
heterodimer is the first protein to arrive at a DSB and recruits DNA-PKcs. Together with
DNA, these factors form the DNA-PK complex. This initial repair complex then recruits
factors required for end-processing and ligation. *The exact order of recruitment of endprocessing and ligating factors is not known at this time. It is possible that processing
enzymes and ligases get recruited at an earlier stage in the NHEJ process (21).
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The Ku heterodimer is evolutionarily conserved in prokaryotic and eukaryotic organisms.
Ku70 and Ku80 do not have similar primary sequences however they share a conserved
secondary and tertiary structure (17, 22). Both subunits bind to each other and form an
asymmetrical basket structure with the basket handle being formed by a ring capable of
binding DNA ends (Figure 1.2A, B). The ring is lined with positively charged basic
residues that favourably interact with the negatively charged sugar-phosphate DNA
backbone. This allows Ku to bind dsDNA ends with high affinity (Kd = 10–9 M), and
circular and single-stranded DNA ends with much lower affinity (17).
In mammals, Ku is a highly conserved and abundant protein. In humans, an estimated
500,000 Ku molecules are present in a single cell at any given time (17). Mammalian
cells spend the majority of their life cycle in the G1 phase, therefore NHEJ functions as
the main dsDNA repair pathway (23).
Unlike HR that is primarily active during S and G2 phases, NHEJ can be utilized at any
point in the cell cycle and has the capacity to join almost any two DNA ends together.
The first step in the NHEJ repair pathway is the recognition of a DSB by Ku (Figure 1.1).
Ku binds the dsDNA ends in a sequence-independent manner then proceeds to act as a
scaffold, interacting with several NHEJ factors and processing enzymes to facilitate the
construction of a DNA repair complex (17). Ku translocates along the DNA and recruits
DNA-dependent protein kinase catalytic subunit (DNA-PKcs) to generate the DNAdependent protein kinase complex (DNA-PK), followed by several auto- and transphosphorylation events of the DNA, Ku and DNA-PKcs itself (Figure 1.1). The
formation of this complex shields against exonucleolytic processing of DNA ends and
minimizes DNA loss (24). Next, Ku mediates recruitment of factors necessary for endprocessing (Figure 1.1) (25). DSB can result in DNA strands having blunt ends, 5’ or 3’
overhangs, 3’ phosphoglycolate termini and DNA adducts. Damaged ends may require
kinases/phosphatases to restore 5′-phosphates required for ligation and/or remove
unligatable 3′-phosphates (26). Depending on the cause and type of DSB, Ku, directly
and indirectly, is responsible for recruiting the correct combination of kinases, nucleases
and polymerases required to produce two compatible DNA ends for ligation. Finally, Ku
is required for the recruitment of the ligase complex,
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A

B

Handle

Body

Figure 1.2: Crystal structure of the Ku heterodimer. Ku70 [blue]/Ku80 [red]) bound
to DNA (green). Structure from Protein Data Bank (PDB; PDB ID = 1JEY) (A) Basket
structure (white labels and arrows) is visible at this top-down view of the DNA helix,
with DNA (green) bound through the ring. (B) Side view of DNA (green) bound through
the ring structure.

7

composed of ligase IV, XRCC4 and XLF (Figure 1.1) (18). The exact timing and order of
recruitment of end-processing and ligating factors is not well characterized. Processing
enzymes and ligases may get recruited at an earlier stage of NHEJ by DNA-PK and not
necessarily in that order (20). After ligation, it is not quite clear how Ku molecules are
removed now that DNA ends, bound through its ring structure, are ligated together. Data
from Xenopus laevis and human cell cultures indicate that ubiquitin-mediated degradation
of Ku80 is important for successful repair of DSBs (27, 28). In yeast, there is evidence
for DNA nicking mechanisms that allow Ku to be freed that is mediated by an HR
complex, Mre11-Rad50-Xrs2 (29).
Experiments conducted in yeast also show that the deletion of Ku results in telomere
shortening, suggesting that Ku also interacts with telomeres and plays an important role
in determining telomere length. The mechanism through which Ku interacts with
telomeres appears to be primarily through promoting the association of telomerase with
telomeres (30–32). This mechanism is separate from NHEJ as DNA ligase IV
deficiency, a protein essential for NHEJ, does not result in altered telomere length in
yeast and mammalian cells (33, 34).

1.4

Ku Knockdown and Knockout Studies

Both Ku70 and Ku80 knockout mouse cell lines have been established as well as
knockout mice and these have been used to gain insight into Ku function. Ku deficient
mice have been shown to live one-third of the lifespan of wild type (WT) mice with
increased senescence and cancer incidences (17, 35). Decreased NHEJ, shorter telomeres
and increased genome instability may contribute to this phenotype. Interestingly, Ku
knockout mice are also dwarfs compared to WT, suggesting Ku may function to regulate
cell growth. Evidently, there are many cellular roles of Ku yet to be discovered.
The following work will focus on Ku in human cells. Thus far, there are no human Ku
homozygous knockout cell lines available to study the role of Ku in human cells. Many
knockdown studies have successfully knocked down Ku70/80 to low levels in many
different human cell lines: human mammary epithelial cell line (36), human proneural
cell lines (37), and CD4+ T cells (38).
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Ku knockouts have previously been attempted in a human colon cancer cell line,
HCT116, targeting Ku80 (39). They were able to create heterozygous knockouts (hetKO)
that displayed slower cell proliferation, shortened telomere, and hypersensitivity to IR.
Homozygous knockouts, created by functional inactivation of the remaining Ku80 copy
in hetKOs, were not viable, dying shortly after inactivation. Ku70 knockouts were later
attempted in HCT116 and Ku70 hetKOs displayed similar phenotype as Ku80 hetKOs:
decreased proliferation, shorter telomeres, and IR hypersensitivity. As such, Ku70
homozygous knockout could not be achieved (40, 41). These results suggest that Ku80,
and Ku70, may be essential for survival (39–41).
These knockout studies suggest that Ku may be essential in human cells. This is also
supported by another knockout study conducted in near-haploid human cell lines (HAP1
and KBM7) that contain only one copy of most chromosomes, including chromosome 22,
which carries the Ku70 gene. Results indicate that Ku70 knockouts were lethal in both
cell lines (42). Furthermore, while several human disorders have been linked to mutations
in many NHEJ factors, no disease has been characterized where Ku subunits have been
mutated (17).
Considering this data, it is quite possible that Ku is essential in humans. However, we
believed that further knockout studies would be valuable, particularly in non-cancerous
and diploid human cell lines. It is possible that cancerous cell lines may have increased
dependence on Ku due to increased genome instability. Thus work here focused on the
generation of Ku knockouts by targeting the Ku70 gene in HEK293 cells, an
immortalized but non-cancerous cell line derived from human embryonic kidney cells
(43). HEK293 cells, although considered non-cancerous, are tetraploid for chromosome
22, where the XRCC6 gene is located (44). Therefore, knockout experiments were also
attempted in human retinal pigmented epithelial (RPE1) cells, a telomerase immortalized
human cell line with a stable diploid genome. They display growth characteristics, and
gene expression patterns comparable to young normal cells (45).
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1.5

Origins of the CRISPR/Cas9 System

A prevalent genome editing tool used to create gene knockouts is the clustered regularly
interspaced short palindromic repeats (CRISPR)/Cas9 system. The CRISPR/Cas9 system,
first discovered in Streptococcus pyogenes, evolved as a form of the bacteria’s adaptive
immunity against plasmids and phages (46). In prokaryotes, this system functions as a
complex comprised of a nuclease, Cas9, and a two-ribonucleic acid (RNA) structure
composed of mature CRISPR RNA (crRNA), which recognizes viral DNA, and transactivating crRNA (tracrRNA), which connects crRNA to Cas9. Fragments of foreign
plasmid or phage DNA, called protospacers, are integrated into the host genome at
CRISPR loci from which the crRNA is transcribed. The crRNA is processed to yield
small mature crRNAs that form a complex with tracrRNA and Cas9 and are used target
exogenous viral and phage DNA for cleavage from where the crDNA originated from
(46). This is analogous to the human adaptive immune system where after exposure to an
antigen either from a pathogen or a vaccine, the human body commits the antigen to
immunological memory through activated B-cells and T-cells that give rise to a more
powerful and efficient immune response upon re-exposure (47). Similarly, with CRISPR,
after a phage attack, viral DNA is preserved by the bacteria and used as a template to
quickly recognize and target future attacks by the same virus. The bacteria are able to
avoid targeting their own genome through the protospacer adjacent motif (PAM). This
short sequence (5’-NGG-3’) must be present downstream of the target site (site
complementary to crRNA) for Cas9 to cleave. By eliminating all PAM sequences from
its CRISPR loci, the bacteria are able to distinguish exogenous from endogenous DNA
(48).
This system has been adapted from S. pyogenes to produce a powerful genome editing
tool. By engineering the two RNA structures together (crRNA + tracrRNA) to create one
RNA chimera (guide RNA), the system has been simplified to an easily programmable
protein:RNA complex (46).
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1.6

Gene Editing Tool: CRISPR/Cas9

The CRISPR/Cas9 system has emerged as the most popular tool for genome editing. The
fusion of crRNA and tracrRNA to make a single guide RNA (gRNA) was an important
breakthrough. It gave scientists the ability to easily program the Cas9 complex to have
various targets through the modification of the gRNA sequence (46). During gene
editing, Cas9 protein forms a complex with gRNA in vivo. CRISPR gRNA is a small
RNA fragment that contains sequence that binds to Cas9 and sequence that is
complementary to the site targeted in the genome. After gRNA binds to Cas9 and a
ribonucleoprotein (RNP) forms, the gRNA guides the RNP to the targeted site. Once
bound to DNA, the Cas9 protein scans the DNA 3’ of the target site for the PAM
sequence, 5’ NGG 3’ (49). If there is a PAM sequence present, then Cas9 creates a blunt
dsDNA break 3 base pairs (bp) upstream of the PAM sequence. Upon the dsDNA break,
the blunt ends undergo either error-prone NHEJ or high-fidelity HR, the two main
dsDNA repair pathways.
The DSB can be ligated back together, which regenerates the target site until there is
exonucleolytic processing of the DNA ends that results in an insertion or a deletion
(indel). A small repair template can be provided for specific HDR to occur at the break
site for applications such as specific gene editing. However, non-homologous end
joining, the major DNA repair pathway in humans, with its ability to perform error-prone
repair while creating a variety of indels is sufficient for producing knockout genes. The
result is a heterogeneous population with numerous genomic modifications of various
sizes of indels. Some of these indels can lead to frameshift mutations that may result in a
knockout of the gene (50). The advantage of this system, contributing to its importance
and prevalence, is its ease of programmability. The gRNA can be designed to target any
site in the gene that is followed by the PAM sequence (5’ NGG 3’).
Another version of the CRISPR/Cas9 system has been discovered in Staphylococcus
aureus. Some advantages of S. aureus Cas9 (SaCas9) over S. pyogenes Cas9 (SpCas9) is
its small size, 1053 amino acids compared to 1369 amino acids and a longer PAM
sequence, 5’-NNGRRT-3’ as opposed to 5’-NGG-3’ (51). Its smaller size increases the
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utility of SaCas9 in research and although the larger PAM limits the number of possible
target sites, it also results in less off-target sites, a major area of concern for SpCas9 (52).

1.7

Gene Editing Tool: CRISPR/TevCas9

An RNA-guided dual nuclease, TevCas9 is another genome editing nuclease that builds
on the CRISPR/Cas9 system. Created by the Edgell lab, TevCas9 is a fusion protein
comprised of the monomeric nuclease and linker domain of a homing nuclease, I-TevI
and the nuclease domain of Cas9 (53). TevCas9 is an improvement on the Cas9 system in
many ways. It is comprised of two nuclease domains that both cleave in a sequencedependent manner which results in deletions of defined lengths in the range of 33 to 36
bp (53).
I-TevI is a site-specific, sequence-tolerant homing endonuclease, encoded by a group I
intron in the thymidylate synthase gene of bacteriophage T4. As a monomer, it has the
ability to cleave and produce a 3’ two base overhang (54, 55). Thus, when linked to the
Cas9 nuclease domain, the complex produces two cleavage events, one blunt cleavage by
Cas9 domain and one 3’ overhang by Tev domain. The Cas9 nuclease domain relies on
gRNA to recognize the target site and functions identical to the protein, Cas9, creating
one blunt DSB. The I-TevI nuclease domain has a recognition sequence of 5’ CNNNG 3’
and it cleaves on the N-terminus side of guanine producing a 2 bp long, 3’ overhang.
Therefore, cleavage with TevCas9 creates two non-compatible ends, minimizing the
possibility of a regenerated target site (53). In contrast, Cas9 stimulates only a single
blunt DSB (49). The TevCas9 system offers the same ease of programmability of the
Cas9 system to select and cleave at a target site. Following discovery of SaCas9, the ITevI nuclease domain has also been fused with SaCas9 to give TevSaCas9.
One application of TevCas9 is the ability to cleave in an exon while targeting gRNA to
an intron close to an intron-exon junction. TevCas9 stimulates a DSB in the intron
through its Cas9 nuclease domain. Additionally, the I-TevI nuclease domain also cleaves
in the exon preceding that intron. This is the central strategy that will be used by this
work to knock out Ku70.
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1.8

Processed Pseudogenes

Ku70 is extremely abundant in human cells (17). The problem is that highly expressed
genes are often prone to producing processed pseudogenes (PP) (17, 56). PPs are created
in germline cells through the reverse transcription and integration of messenger RNA
(mRNA) into random locations in the genome (56, 57). Highly expressed genes require
the production of large amounts of mRNA. This can result in the generation and
integration of one or multiple pseudogenes into the genome. These PPs are often nonfunctional and have lost the ability to produce proteins (56, 58).
This is the case with the Ku70 gene. Ku70 is located on chromosome 22. However, it has
five pseudogenes present in the human genome (XRCC6P1-5). Three pseudogenes are
found on chromosomes 1, 8 and 10 and two pseudogenes are both found on chromosome
X. Consequently, it is not possible to directly target a Ku70 exon as there may be up to
five identical sites present on other chromosomes. Multiple DSBs on the same or
different chromosomes can result in mutagenic or lethal chromosomal rearrangements,
such as translocations (59). As PPs are generated by reverse transcription of mRNA,
these pseudogenes do not contain the intronic region found in the original gene.
Therefore, to knockout Ku, it is necessary to target an intron, ensuring that none of its
pseudogenes are targeted.

1.9

Objectives

1. To generate viable Ku70 knockouts in HEK293 cells: If Ku70 knockout cells are
viable, cell lines will be phenotypically characterized. If we cannot knockout Ku,
then the goal is to demonstrate that Ku70 is required for human cell viability.
2. To demonstrate that targeting the intron-exon junction is a feasible strategy to
disrupt Ku70: If successful, the knockout strategy employed in this work can be
generalized to knockout other highly expressed genes that may have multiple
pseudogenes present in the genome. PPs do not contain introns; thus, intron
region from the original gene near an intron-exon junction is an ideal target. With
TevCas9, it is possible to get cleavage in the exon itself, while only targeting the
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intron. With Cas9, this is much less likely and depends solely on exonucleolytic
processing to create deletions large enough to extend into the exon, demonstrating
TevCas9 is both necessary and sufficient in addressing more challenging
knockout targets.

1.10 Rationale: Target Site
The strategy was to target an intron just upstream to an intron-exon junction in Ku70
(Figure 1.3A, B). While working with SpCas9, the junction between exon 10 and the
subsequent intron was targeted (Figure 1.3A). When working with SaCas9, three intronexon junctions were simultaneously targeted (Figure 1.3B). A gene knockout can be
achieved through partial exon deletions stimulated by dual cuts made by TevCas9. With
Cas9, the knockout efficiency depends on error-prone NHEJ and the possibility of large
deletions that may extend from the cleavage site in the intron to the preceding exon
(Figure 1.3B).

1.11 Conditional Knockout: Strategy to Address Lethality of Ku70
Knockouts
Genes essential to cell viability, as Ku70 is suspected to be, cannot be directly knocked
out. Therefore, we planned to create conditional Ku70 knockout cells. To address the
possibility of lethality, a HEK293 stable cell line containing a human influenza
hemagglutinin (HA) tagged exogenous copy of Ku70 (Ku70-HA) under the control of a
tetracycline-inducible promoter was used for knockout studies. This second copy of Ku70
was expected to compensate for the loss of endogenous Ku70 and maintain knockout
viability. The CRISPR system was used on these stable cells lines to knockout the
endogenous copy of Ku70. Once knockouts are obtained, exogenous Ku70-HA
expression was shut off. Cell death, under this condition, was used to indicate whether
knockout of Ku70 was lethal in HEK293 cells.
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A

PAM

B

Figure 1.3: Ku70 sites targeted by gRNA for TevCas9 and Cas9 variants. (A) Ku70
target site for TevSpCas9 and SpCas9. Both nucleases use the same gRNA. The red
lines indicate the cleavage sites for both enzymes. Cas9 stimulates one blunt DSB three
bp upstream of the PAM sequence. TevCas9 generates two DSB, one 3 bp upstream off
the PAM sequence and one in the preceding exon. (B) Ku70 target site for TevSaCas9
and SaCas9. The gRNA is targeting the template strand, instead of the coding strand.
The PAM site (5’-GGGAGT-3’) is present in the intron, thus will not be present in
Ku70’s pseudogenes. Cas9 cleaves just one bp outside the intron-exon junction, while
TevCas9 makes an additional cleavage downstream in the exon.
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Chapter 2

2

Methods

2.1

Plasmid Constructs

px458SpCas9GFP (SpCas9-2A-GFP) and px459SpCas9PuroR (SpCas9-2A-puro) vectors
were previously obtained from Feng Zhang through Addgene (Addgene plasmid # 48138
and plasmid # 62988) for transfection into mammalian cell lines (50). The nuclease,
SpCas9, is linked to green fluorescence protein (GFP) and a puromycin resistance
marker, respectively. TevSpCas9 dual nuclease was created by Jason Wolfs by cloning ITevI (amino acids 1–169) in front of the N terminus of SpCas9 to create
px458TevSpCas9GFP and px459TevSpCas9PuroR.
The SaCas9 construct was created by Jasmine Therrien. SpCas9 was excised out and full
length SaCas9 was cloned into px458SpCas9GFP. Polymerase chain reaction (PCR)
amplification of the pac gene encoding puromycin N-acetyl-transferase from
px459SpCas9PuroR was used to clone puromycin resistance into this construct to create
px458PuroRSaCas9GFP. px458PuroRTevSaCas9GFP was constructed by cloning I-TevI (amino
acids 1–169) in front of the N terminus of SaCas9 by Dr. Thomas McMurrough.
The pBIG2R-Ku70 tetracycline repressible plasmid was created previously by Elizabeth
Walden by cloning full length Ku70 into the multiple cloning site of the pBIG2r vector
(60). To allow pBIG2R Ku70 expression to be distinguished from endogenous Ku70
expression, I subcloned an HA-tag to the C-terminus of Ku70 in pBIG2R-Ku70. The
pBIG2R-Ku70-HA vector allows for transfection and tetracycline repression of Ku70HA expression in mammalian cell lines.
To create pcDNA5/FRT/TO-Ku70-HA, for the TREX Ku70-HA tetracycline repressible
system, I PCR-amplified full length Ku70-HA from pBIG2R-Ku70-HA using primers
containing restriction enzyme sites and cloned it into pcDNA5/FRT/TO.
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2.2

Designing gRNA

Since Ku70 has five pseudogenes that contain only exons from endogenous Ku70, gRNA
was designed to target intron-exon junctions in Ku70. A script made by Dr. Edgell was
used to locate potential Cas9 and TevCas9 target sites in Ku70 (Figure 2.1). This script
searched the Ku70 DNA sequence for regions that spanned intron-exon junctions and had
to the consensus sequence required for Tev nuclease and Cas9 nuclease cleavage. The
consensus sequence for SpCas9 and TevSpCas9 target sites was 5‘ CNNNG(N)34-40NGG
3’ and for SaCas9 and TevSaCas9 target sites was 5‘ CNNNG(N)34-40NNGRRT 3’.
5‘ CNNNG 3’ is the consensus sequence required for Tev nuclease cleavage. 5‘ NNG 3’
is the PAM sequence for SpCas9 while 5‘ NNGRRT 3’ is the PAM sequence for SaCas9
required for Cas9 cleavage.
Ku70 knockout was attempted using following gRNAs:
•

SpCas9 & TevSpCas9
o Target 0: 5‘ AGTCAATCTCAGGCTTTC 3’

•

SaCas9 & TevSaCas9
o Target 1: 5’ AGCTTCAGCTTTAACCTGA 3’
o Target 2: 5’ ACTCAGCAGGTGTGCACTCAGC 3’
o Target 3: 5’ TCATTGCTTCAACCTTGGGCAC 3’

These gRNAs were used to guide the Cas9 nuclease in Cas9 and TevCas9. All of the
target sites chosen spanned both intronic and exonic region of the Ku70 gene (Figure
2.1). TevCas9 had an additional cut site present upstream of the gRNA in these target
sites determined by the Tev nuclease consensus sequence of 5’ CNNNG 3’. Target site 0
was used with SpCas9, thus used the PAM 5’ NGG 3’. Target site 1-3 were used with
SaCas9, thus use the PAM 5’ NNGRRT 3’.
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PAM

Figure 2.1: Four target sites used in Ku70 knockout experiments. Target sites were
located using a script by Dr. Edgell. They span both the intronic and exonic region of the
Ku70 gene. Target site 0 was used with SpCas9, thus used the PAM site 5’ NGG 3’.
Target site 1-3 were used with SaCas9, thus use the PAM site 5’ NNGRRT 3’.
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2.3

Golden Gate Assembly

gRNAs were ordered in the form of synthesized oligonucleotides with BbsI cut site
compatible overhangs added to each side. The designed gRNA was cloned into
px458SpCas9GFP, px458TevSpCas9GFP, px459SpCas9PuroR, and px459SpCas9PuroR. This
was accomplished using Golden Gate assembly, following the protocol outlined in Engler
et al., 2008 (61). However, the restriction enzyme BbsI was used instead of BsaI. After
Golden Gate assembly, heat shock transformation was performed using Escherichia coli
(DH5α) competent cells to amplify the plasmid. An overnight liquid culture was prepared
from individual colonies from the transformation and the next day, the plasmid was
purified using EZ-10 Spin Column Plasmid DNA Miniprep Kit by (Bio Basic Inc).
Correct gRNA insertion was confirmed by DNA sequencing.

2.4

Tissue Culture of Cell Lines

HEK293 cells (ATCC® CRL-1573) were grown at 37°C in a 5% CO2 incubator and
cultured in Dulbecco's Modified Eagle's medium (DMEM) (Wisent Inc.) to which 8%
fetal bovine serum (FBS) (Wisent Inc.), 1% L-glutamine (Wisent Inc.), and 1% sodium
pyruvate (Wisent Inc.) were added.
HEK293 TREX cells (Invitrogen Canada Inc.) were gifted by Dr. Murray Junop’s Lab.
Cells were grown at 37°C in a 5% CO2 incubator and cultured in DMEM (Wisent Inc.) to
which 10% FBS (Wisent Inc.) and 1% L-glutamine (Wisent Inc.), and 1% sodium
pyruvate (Wisent Inc.) were added. RPE1 cells (ATCC® CRL-4000) were grown at 37°C
in a 5% CO2 incubator and cultured in DMEM/F-12 medium (Wisent Inc.) to which 8%
FBS (Wisent Inc.) and hygromycin B (Wisent Inc.) to the final concentration of 0.01
mg/ml were added.
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2.5

Antibiotic Concentrations

Table 2.1. Antibiotic concentrations used for each cell line. Antibiotic concentrations
used for selection, maintenance or inducing gene expression categorized by cell line.

ANTIBIOTIC

CELL LINES
HEK293

HEK293 TREX

RPE1

Blasticidin

-

15 μg/mL

5 μg/mL

Doxycycline

0.5 μg/mL**

1 μg/mL **

-

G418

450 μg/mL

450 μg/mL

800 μg/mL

Hygromycin

50 μg/mL

150 μg/mL

10 μg/mL *

Puromycin

1.2 μg/mL

-

2.5 μg/mL

Tetracycline

6 μg/mL **

-

-

Zeocin

-

100 μg/mL

-

(*) indicates concentration for cell maintenance
(**) indicates concentration for gene expression induction
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2.6

Transfections

2.6.1

jetPRIME

All jetPRIME transfections were performed using jetPRIME Versatile DNA/siRNA
transfection reagent, following the manufacturer’s instructions (Polyplus Transfection
Inc). Antibiotic was added 24-48 hours after transfection for selection (Table 1).

2.6.2

Lipofectamine

All Lipofectamine transfections were performed using Lipofectamine 3000 transfection
reagent, following the manufacturer’s instructions specific for 6-well plates
(ThermoFisher Scientific Inc). Cells were seeded in 6-well plates 24 hours before
transfection to reach 70-90% confluency at time of transfection. Antibiotic was added 48
hours after transfection for selection (Table 1).

2.6.3

Calcium Phosphate

Cells were seeded in a 10 cm dish, 24 hours before transfection to reach 80-90%
confluency at time of transfection. One hour before transfection, cell media was
replenished with fresh media. During the transfection, 11 ug of DNA was diluted in the
appropriate amount of H2O to reach a final volume of 438 uL. 62 uL of 2M CaCl2 was
added to the DNA-H2O solution. Next, HEPES-buffered saline (HBS) (25 mM
hydroxymethyl piperazineethanesulfonic acid (HEPES) pH 7.4, 140 mM NaCl, 6 mM
dextrose, 0.75 mM Na2HPO4, and 5 mM KCl) was added to the DNA-CaCl2 solution.
The final mixture was aerated using a pipet for 1 min, then added dropwise to the cells.
Cells were incubated for 18 hours before media was replaced with fresh media. Antibiotic
was added 24-48 hours after this step for selection (Table 1).

2.7

DNA Extraction

DNA was extracted from cells using QuickExtract DNA Extraction Solution (Lucigen
Corporation). Human cells were harvested and pelleted in an Eppendorf tube at 8000 rpm
for 3 minutes. The pellet was washed with phosphate-buffered saline (PBS; Wisent) to
remove residual DMEM. The pellet was dissolved in 20-80 uL of QuickExtract solution
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using vortexing. The mixture was heated at 65°C for 6 minutes, vortexed for 10 seconds,
and heated at 98°C for 2 minutes. The mixture was cooled to room temperature for
downstream application.

2.8

Nested Polymerase Chain Reactions

Nested PCR were performed to amplify the TevCas9/Cas9 target site from the extracted
genomic DNA (Table 2). Nested PCR were conducted using 2 nested pairs of primers,
and 2 consecutive PCR reactions. Nested PCR #1 was conducted using genomic DNA as
template and Nest #1 primers for each site. This PCR mixture was then used as the
template for Nested PCR #2 that was conducted using Nest #2 primers for each site.

2.9

Cleavage Resistance Assay

Nested PCRs were performed to amplify the TevCas9/Cas9 target site 0 from the
extracted genomic DNA (Table 2.2). The final PCR product was 970 bp long. The
TevCas9 target site is located at an intron-exon junction. In the target site, there was a
cleavage site for the restriction enzyme, MslI. It was located at the edge of the intronexon junction (Figure 2.2). In this assay, the PCR product was digested with MslI.
Digestion produced 2 fragments of 685 bp and 285 bp. If there were any DNA
modifications in the MslI cut site, it resulted in resistance to cleavage by MslI. Cleavage
products were visualized using gel electrophoresis.
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Table 2.2. Primers for nested PCR.
Sequence

Tm (°C)

Nest #1 forward primer

ctgtaatcccagcactttgg

56.1

Nest #1 reverse primer

gcaggctctgagagttggtc

58.6

Nest #2 forward primer

ccccatctttaccgaaagtac

56.2

Nest #2 reverse primer

caatcaaggagaagggcg

57.7

Nest #1 forward primer

gagcaccgacctaatgttc

53.0

Nest #1 reverse primer

ccccagtcgatccagtctc

57.0

Nest #2 forward primer

gggttgggaatattcaaccag

53.5

Nest #2 reverse primer

gtcacatgcctgtgatccc

55.9

Nest #1 forward primer

cagatggccatgccatta

52.6

Nest #1 reverse primer

ctgagtagctgggactac

51.2

Nest #2 forward primer

acggagtctcactctgtc

53.2

Nest #2 reverse primer

caagctgtactctctggg

52

Nest #1 forward primer

ggataaggcctaattccttgg

52.9

Nest #1 reverse primer

ggtaaccatccttctatgctc

52.5

Nest #2 forward primer

gtcacctgctatttctctcc

52.5

Nest #2 reverse primer

gacacaagttgcttccag

51.1

PCR product

Target Site 0
1182 bp

970 bp

Target Site 1
812 bp

694 bp

Target Site 2
1657 bp

1452 bp
Target Site 3
1618 bp

1402 bp
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Figure 2.2. MslI cut site for the cleavage resistance assay. The MslI cut site is in
capitalized letters. It spans the end of exon 10 and extends 3 bp into the intron.
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2.10 T7 Endonuclease I Assay
T7 Endonuclease I (T7E1) assay was conducted following the extraction of genomic
DNA from a population of transfected cells and PCR amplification of the target site.
T7E1 (New England BioLabs Inc.) was used for this assay. First, an annealing reaction
was set up composed of 200 ng of PCR-amplified DNA, 2 ul of NEBuffer 2 and water for
a final reaction volume of 19 uL. This solution was heated in a thermocycler at 95°C for
5 minutes, then cooled at the rate of 2°C/second to 85°C, and finally cooled at the rate of
0.1°C/second to 25°C. T7E1 was then added (1 µL) to the annealed PCR products and
incubated at 37°C for 15 minutes. T7E1, which indicates editing, was visualized by
running the reaction on an agarose gel.

2.11 Target Locus Analysis
Tracking of Indels by DEcomposition (TIDE) is a webtool to assess genome editing at a
target locus by CRIPSR-Cas9 (64). Analysis required the sequence of the gRNA, an
electropherogram from Sanger sequencing reactions of the CRISPR-treated PCRamplified target site, and an electropherogram from a control PCR-amplified target site.
Using sequencing data, TIDE identified editing efficacy and the predominant types of
insertions and deletions at the tested target site.

2.12 Western Blotting
Western blotting of protein was performed following the protocol outlined by Mahmood
and Yang, 2012 with the following exceptions (65). A Bradford protein assay was used to
quantify protein concentration (66). A sample of 10-35 µg of protein was loaded for each
protein sample analysed. The Bio-Rad Trans-Blot Turbo transfer system, a semi-dry
transfer method (Bio-Rad Laboratories, Inc.), was used to transfer protein from gel to a
polyvinylidene fluoride membrane. Transfers were conducted at 2.5 amperes and 25
volts for 25 minutes.
Following transfer, the blot was blocked for 1 hour in 5% non-fat dry milk powder
(Carnation®) prepared in Tris-buffered saline with Tween-20 (TBS-T; 50 mM Tris-Cl pH
8, 150 mM NaCl and 0.05% Tween-20) and incubated with primary antibodies diluted in
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5% milk in TBS-T for 1 hour at room temperature or at 4°C overnight. After incubation,
the blot was washed three times in a TBS-T solution before it was incubated with
secondary antibody dissolved in 5% milk powder in TBS-T. The antibody complex was
visualized using Clarity Western ECL Blotting Substrates (Bio-Rad Laboratories Inc.)
and imaged using a ChemiDoc MP (Bio-Rad Laboratories Inc.). Images were analysed
using Image Lab software (Bio-Rad Laboratories Inc.).

2.13 Immunofluorescence
Cells were seeded onto coverslips and incubated overnight. Cells were washed three
times in phosphate-buffered saline (PBS; 137 mM NaCl, 10 mM phosphate, 2.7 mM
KCl, and pH 7.4) and fixed on coverslips using 4% paraformaldehyde (BioShop Canada
Inc.) for 15 minutes at 4°C. Coverslips were washed three times with PBS and cells were
permeabilized using 0.5% Triton X-100 (BioShop Canada Inc.) for 15 minutes, followed
by three washes with PBS. Coverslips were blocked in 5% FBS (Wisent Inc.) diluted in
PBS for 1 hour at room temperature.
Coverslips were incubated overnight at 4°C with agitation in primary antibody diluted in
5% FBS (Wisent Inc.). Coverslips were washed three times with PBS then incubated with
AlexaFluor 488 anti-mouse secondary antibody (Invitrogen Canada Inc.) for 1 hour at
room temperature in the dark. Cells were washed three times with PBS then mounted on
glass slides using ProLong® Gold antifade with 4′,6-diamidino-2-phenylindole (DAPI;
Invitrogen Canada Inc.). Slides were imaged using an Olympus BX51 microscope
(Olympus Corporation) and Image-Pro Plus software (Media Cybernetics Inc.). Images
were analysed with ImageJ.

2.14 Antibodies
Primary antibodies used were Ku70 (N3H10; Santa Cruz Biotechnology, Inc.), Ku80
(M20; Santa Cruz Biotechnology, Inc.), Human influenza hemagglutinin for western
blotting (H3663; Santa Cruz Biotechnology, Inc.), HA for immunofluorescence (H9658;
Santa Cruz Biotechnology, Inc.), -Actin (A5414; Sigma-Aldrich), Vinculin (E1E9V;
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Cell Signaling Technology), and α-Tubulin (T5168; Sigma-Aldrich). Antibody
concentrations can be found in Table 3.

2.15 Statistical Analysis
Error bars indicating standard error of the mean are present on bar graphs. T-tests and
error bar calculations were completed on GraphPad (GraphPad Software Inc.). Analysis
by t-test resulting in a p-value of less than 0.001 conferred significance.
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Table 2.3. Primary antibodies, their respective dilutions, and company
Antibody

Article number

Dilution

Company

HA [Western Blot]

H3663

1:1000

Santa Cruz

HA [Immunofluorescence]

H9658

1:1000

Sigma-Aldrich

Ku70

N3H10

1:1000

Santa Cruz

Ku80

M20

1:200

Santa Cruz

-Actin

A5414

1:20000

Sigma-Aldrich

α-Tubulin

T5168

1:10000

Sigma-Aldrich

Vinculin

E1E9V

1:10000

Cell Signaling
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Chapter 3

3

Results

3.1

Overview

Previous studies suggest that the evolutionarily conserved Ku heterodimer may be
essential in human cells (39–41). Thus far, viable Ku knockout cell lines have only been
successfully created in mouse cell lines and mice (17).
Since Ku exists and functions as an obligate heterodimer, targeting one subunit of Ku
results in diminished expression of the other subunit (19, 67). Ku knockout studies have
been conducted in a human colon cancer cell line, HCT116 by targeting both Ku70 and
Ku80 independently (39, 40, 68). They found that heterozygous knockouts were viable
but homozygous knockouts were not viable, implying that Ku80 and Ku70 were essential
proteins in humans. We believe that further knockout studies would be valuable,
particularly using other non-cancerous cell lines such as HEK293 cells and RPE1 cells.
The goal of this project was to evaluate whether the knockout of Ku70 is lethal in human
cells and to generate Ku70 knockouts to be used as a tool to further study the role of Ku
in human cells. The tool we will be using to make these knockouts is a popular genome
editing tool CRISPR/Cas9 system and the dual nuclease variation, CRISPR/TevCas9
system.

3.2

Attempt to Knockout Ku70 in WT Hek293 Cells

Ku70 knockouts were initially attempted in WT HEK293 cells. Preliminary experiments
using live fluorescence imaging and cleavage resistance assays were conducted in WT
HEK293 cells and the results suggested that TevSpCas9 and SpCas9 were expressing and
cleaving in vivo (Figure 3.1). WT HEK293 cells were initially transfected with px458
plasmid carrying TevSpCas9 or SpCas9. Live-cell imaging revealed that TevCas9 was
being transfected at higher levels compared to SpCas9 and no-gRNA plasmid
transfection efficiency was lower than the gRNA-containing counterpart (Figure 3.1B).
PCR-amplified product of target site 0 (Table 2.1) from genomic DNA extracted from
transfected cells was digested with MslI. Digestion was expected to produce 2 fragments,
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685 bp and 285 bp in length. Resistance to cleavage would indicate that the MslI site,
located within the SpCas9/TevSpCas9 target site has been removed (Figure 2.2). Faint
resistance bands were visualized on the cleavage resistance assay suggesting that
TevSpCas9 and SpCas9 were cleaving in vivo (Figure 3.1A).
The transfected cell population was selected with puromycin for 5 days, after which
puromycin was removed. Colonies were grown, then picked and cultured as monoclonal
cell lines. Monoclonal cell lines were screened through western blotting (Figure 3.2). A
total of 22 monoclonal cell lines were screened, and none of the cell lines showed
decreased or abolished expression of Ku70 indicating that none of the clones were Ku70
knockdowns or knockouts.
Compared to the SpCas9 transfected cells, there was 2- to 3-fold greater cell death in the
TevSpCas9 transfected cells (data not shown). Control cells transfected with SpCas9 and
TevSpCas9 without gRNA died completely under antibiotic selection (data not shown).

3.3

Attempt to Knockout Ku70 in HEK293 Ku70-HA Stable
Cells

We created a HEK293 stable cell line with an inducible second, exogenous copy of Ku70
controlled by a tetracycline-off (Tet-OFF) promoter. HEK293 cells were transfected with
pBIG2r Ku70-HA constructs. Using hygromycin selection, a polyclonal HEK293 Ku70HA cell line was created. To determine if and to what percentage the polyclonal stable
cell line had integrated Ku70-HA, immunofluorescence was conducted with an HA
antibody (Figure 3.3A). The immunofluorescence indicated that over 90% of the cells
expressed Ku70-HA.
pBIG2R is a Tet-OFF system therefore gene expression of Ku70-HA in these cells can be
shut off by the addition of either tetracycline or doxycycline. First, we confirmed that the
Ku70-HA Tet-OFF system was functioning (Figure 3.3B, 3.3C). The addition of
tetracycline for 5 days resulted in a decrease but not a complete shutdown of Ku70-HA
expression (Figure 3.3B). Reduction in Ku70-HA did not appear to have a substantial
effect on total Ku70 levels. Total Ku70 levels resembled the levels of the loading control,
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A

B

Figure 3.1A. Cleavage resistance assay to detect genome editing in regular HEK293
cells. TevCas9 and Cas9 with and without gRNA were transfected into HEK293 cells.
Transfected cell populations were harvested 24 hours after transfection. Harvested
samples were mock (no DNA was transfected), pMSCVpuro (control vector without
CRISPR was transfected), Cas9 – gRNA (no-gRNA), Cas9 + gRNA (with gRNA),
TevCas9 – gRNA (no-gRNA), TevCas9 + gRNA (with gRNA). (*) indicated DNA
harvested from separate transfections. DNA was extracted and amplified using nested
PCRs and digested with MslI. Undigested (U) and MslI-digested (D) samples were run
on a 1.5% agarose gel for 50 minutes at 90 V. Red arrows indicate the band suggesting
resistance to MslI cleavage. B. Live fluorescence and contrast imaging of GFP-tagged
SpCas9 and TevSpCas9 transfected HEK293 cells. Visualized 24 hours after
transfection. Top pane: HEK293 population under white light. Bottom pane:
Visualization of GFP under blue light (488 nm) indicating nuclease expression. White
bars denote 50 μm.
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Figure 3.2: Western blot probing for Ku70 expression in HEK293 monoclonal cell
lines. Samples were taken from SpCas9 (C) or TevSpCas9 (T) monoclonal cell lines or
pooled cells. 20 monoclonal samples and 2 samples from entire populations were
analysed. The blot was probed with anti-Ku70 and anti-alpha tubulin antibodies. Tubulin
was used as a loading control. Underlined samples were extracted from a population and
are not monoclonal cell lines. The red and blue squares indicated samples run twice on
western blots. (*) indicated monoclonal cell lines isolated from co-transfection of
px458SpCas9GFP (carrying the nuclease) and pMSCVpuro (carrying puromycin
resistance).
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Actin (Figure 3.3B). This repression experiment was repeated using the antibiotic,
doxycycline, which was kept on cells for 7 days instead of 5 days (Figure 3.3C). This
resulted in better repression and very little expression of Ku70-HA after 7 days. This
confirmed that we had a HEK293 cell line with Ku70-HA stably integrated under an
inducible Tet-OFF promoter.
All further CRISPR experiments were conducted using px458neoRSaCas9GFP and
px458neoRTevSaCas9GFP constructs. Both SaCas9 and TevSaCas9 in these constructs
were T2A linked to GFP. T2A linker encodes a short DNA sequence that is translated
into a self-cleaving peptide. The nuclease (SaCas9 or TevSaCas9) and GFP are
transcribed on one mRNA. However, after translation, the linker will self-cleave and
separate the nuclease and GFP into separate proteins. Live-cell imaging was used to
detect protein expression of GFP and indirectly, of SaCas9 and TevSaCas9, 24 hours
after transfection. The presence of GFP in these cells indicated that SaCas9 and
TevSaCas9 were transfected and expressed in HEK293 Ku70-HA cells (Figure 3.4).
Following transfection, these cells were selected with G418 antibiotic to select for cells
containing px458neoRSaCas9GFP or px458neoRTevSaCas9GFP plasmids and monoclonal
colonies were subsequently isolated and analysed.
SaCas9 and TevSaCas9 were transfected into these cells and monoclonal colonies were
isolated and analysed. Out of over 40 analysed clones, two clones showed the highest
reduction of Ku70 by Western blotting, clones 22 and 27 (Figure 3.5). When analysed
genomically through sequencing, these clones showed heterozygous mutations that
extended into the exon and disrupted the Ku70 splice site. Clone 22 contained a 54 bp
heterozygous deletion, and clone 27 contained a 19 bp heterozygous deletion (Table 3.1).
No growth defects such as abnormal cell morphology or change in cell growth rate were
observed.
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A

B

C

Figure 3.3A. Immunofluorescence probing for Ku70-HA expression in HEK293
Ku70-HA stable cells. Expression and cellular localization of Ku70-HA were visualized
using immunofluorescence of HEK293 Ku70-HA cells stained with DAPI (blue) and
probed with anti-HA antibody (green). White bars denote 50 μm. B. Western blot
analyses of tetracycline-induced repression of Ku70-HA in HEK293 Ku70-HA
stable cells. Whole cell extracts taken from HEK293 Ku70-HA cells that were treated
with tetracycline (6 μg/mL) for 0 days and 5 days. Blot was probed with anti-Ku70, antiKu80, anti-HA and anti-actin antibodies. C. Western blot analyses of doxycyclineinduced repression of Ku70-HA in HEK293 Ku70-HA stable cells. Whole cell
extracts taken from HEK293 Ku70-HA cells that were treated with doxycycline (0.5, 1,
2, 3, and 4 μg/mL) for 7 days. Blot was probed with anti-Ku70, anti-HA and anti-actin
antibodies.
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Figure 3.4. Fluorescence and contrast imaging to visualize transfection efficiency in
HEK293 Ku70-HA cells. Cells were transfected with no DNA, SaCas9-GFP (with and
without gRNA), and TevSaCas9-GFP (with and without gRNA) containing plasmids and
visualized 24 hours after transfection. The top row shows HEK293 population under
white light. The middle row shows the visualization of GFP excited under blue light (488
nm) indicating nuclease expression in fluorescing cells. The bottom row is the top two
rows overlaid to show the position of cells relative to the position of fluorescence. White
bars denote 1000 μm.
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Figure 3.5A. Western blot analyses of Ku70 expression in SaCas9 transfectionderived HEK293 Ku70-HA monoclonal cell lines. Whole cell extracts taken from
monoclonal HEK293 Ku70-HA cells transfected with SaCas9 and selected with G418.
Blot was probed with anti-Ku70 and anti-actin antibodies. B. Quantitative analyses of
Ku70 levels in SaCas9 transfection-derived HEK293 Ku70-HA stable cells. Ku70
levels in SaCas9 transfection-derived HEK293 Ku70-HA monoclonal cell lines were
quantified compared to WT HEK293 Ku70-HA control and averaged for each clone
(n=3).
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Table 3.1. Genetic analyses of HEK293 Ku70-HA monoclonal cell lines after
CRISPR treatment. Monoclonal cell lines were picked from CRISPR-transfected
HEK293 Ku70-HA cells after G418 selection. The gRNA targeted site was PCRamplified and sequenced. Electropherograms were analysed manually and using TIDE to
determine the size of the editing event and if the editing affected the intron-exon splice
site. The table shows the genetic analyses of all clones that showed editing events.
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3.4

Ku70 Gene Editing in RPE1 Cells

Experiments were halted in HEK293 Ku70-HA cells and switched to RPE1 cells for
several reasons. The HEK293 Ku70-HA clones became contaminated with fungi and
could not be used in experiments any further. Additionally, some of the sequencing
electropherograms of the HEK293 Ku70-HA clones contained more than two signals.
This indicated that HEK293 cells carries more than two copies of the gene that encodes
Ku70. Literature searches confirmed that HEK293 cells are tetraploid for chromosome
22, the chromosome that carries the Ku70 gene (44). RPE1 cells are a near-diploid cell
line (45) which we believe may better mimic ‘normal’ human cells compared to
polyploid cell lines such as HEK293. This would help generalize results from immortal
cells to normal human cells.
First, Ku70 levels in RPE1 and HEK293 cells were compared. As expected from the
respective Ku70 gene copy number, we found that RPE1 cells had significantly less Ku70
levels (Figure 3.6). Preliminary transfections were conducted to optimize transfection
efficiency in RPE1. RPE1 cells on average had lower transfection efficiency compared to
HEK293 cells. We found that by using Lipofectamine 3000 (Thermo Fisher Scientific
Inc.) we were able to get 10 to 20% transfection efficiency (Figure 3.7).
Ku70 CRISPR knockouts were attempted in WT RPE1 cells. Interestingly, 24 hours after
CRISPR transfection, cells transfected with gRNA showed more death in comparison to
cells transfected with no-gRNA as control (Figure 3.8).
RPE1 cells transfected with SaCas9 or TevSaCas9 with Ku70 targeting gRNA were also
harvested 24 hours after transfection. Genomic DNA was extracted from the cell
population and target site 1 was PCR-amplified using nested PCRs. The PCR product
was sequenced and analysed using TIDE to determine the amount of editing present and
most common insertion or deletion events. In the SaCas9 transfected population, the total
editing efficiency was found to be 2.2%, with the most common editing event being a 1
bp insertion event. In the TevSaCas9 transfected population, the total editing efficiency
was calculated as 8.7%, with the most common editing event being a 36 bp deletion
(Figure 3.9).
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Figure 3.6A. Western blot analyses of Ku70 levels in RPE1 cells and HEK293.
Whole cell extracts from WT RPE1 and HEK293 were analysed using sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Blot was probed with antiKu70 and anti-alpha tubulin antibodies as loading control. B. Quantitative analyses of
Ku70 levels in RPE1 cells and HEK293. Ku70 levels in WT RPE1 cell were quantified
compared to WT HEK293 control and averaged for each cell line (n=3) (*** p<0.001).

Figure 3.7. Overlay of live-cell fluorescence and contrast imaging to visualize
transfection efficiency in RPE1 cells. RPE1 cells were transfected with no DNA,
SaCas9-GFP, and TevSaCas9-GFP containing plasmids. 24 hours after lipofectamine
transfection RPE1 population was visualized under white light (contrast imaging) and
blue light (488 nm; GFP fluorescence imaging) and images were overlaid. Presence of
GFP fluorescence indicated nuclease expression in cells. White bars denote 1000 μm.
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Figure 3.8. Overlay of fluorescence and contrast imaging visualizing transfection
efficiency and confluency of RPE1 cells. Samples were transfected with no DNA,
SaCas9-GFP + Rmnd5A gRNA, SaCas9-GFP no-gRNA, SaCas9-GFP + Ku70 gRNA,
TevSaCas9-GFP, and TevSaCas9-GFP + Ku70 gRNA-containing plasmids. RPE1
population under white light and blue light (488 nm) was visualized 24 hours after
jetPRIME transfection and images were overlaid. GFP fluorescence indicated nuclease
expression in fluorescing cells. White bars denote 1000 μm.
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Figure 3.9. TIDE analyses of gene editing events in SaCas9 and TevSaCas9
transfected RPE1 cells. 24 hours after transfection, population of SaCas9 or TevSaCas9
transfected RPE1 cells were harvested and DNA was extracted. The gRNA targeted site
was PCR-amplified and sequenced. Electropherograms were analysed using TIDE to
determine the size of common editing events in each population.
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RPE1 cells transfected with SaCas9 and TevSaCas9 with Ku70 targeting gRNA were
selected with G418 for 7 days. G418 was removed and colonies are grown and picked. A
total of 45 clones, picked from two separate transfections, were screened. Figure 10A
shows Ku70 expression of a portion of clones. None of the clones screened completely
lacked Ku70 expression but some clones appeared to have decreased Ku70 levels.
However, when further screening was conducted using T7 endonuclease I assays, no
genome editing was found (Figure 3.10B). Multiple attempts were made to create RPE1
Ku70-HA stable cells, however, none were successful.

3.5

HEK293 TREX Ku70-HA Cells

While attempting to create the inducible Ku70-HA system in RPE1 cells, I also recreated
HEK293 Ku70-HA stable cells in parallel, as previous research in HEK293 Ku70 was
disrupted due to fungal contamination.
I was able to generate HEK293 TREX TET-ON Ku70-HA stable cells. The HEK293
TREX cell line constitutively expresses the tetracycline repressor. Cells were transfected
with a plasmid carrying Ku70-HA under control of a tetracycline operon. In the absence
of tetracycline (or doxycycline), the tetracycline repressor protein bound to the operon
and repressed transcription of Ku70-HA. If tetracycline or doxycycline antibiotics were
added, they bound the tetracycline repressor and did not allow it to block transcription of
the promoter, thus inducing expression of Ku70-HA.
This stable cell line was created using a different inducible system compared to
previously. The initial HEK293 Ku70-HA stable cells used a TET-OFF system and were
polyclonal with over 90% of cells showing Ku70-HA expression. HEK293 TREX Ku70HA stable cells were a tetracycline-ON (TET-ON) system and isogenic polyclonal with
100% of cells showing Ku70-HA expression as visualized by immunofluorescence
(Figure 3.11).
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Figure 3.10A. Western blot analyses of Ku70 levels in CRISPR RPE1 cells
monoclonal cell lines. Whole cell extracts from RPE1 CRISPR monoclonal cell lines
were analysed using SDS-PAGE. Blot was probed with anti-Ku70 antibody and antialpha tubulin antibody as a loading control. B. Agarose gel showing T7EI assay to
detect genome editing in RPE1 CRISPR monoclonal cell lines. DNA was extracted
from RPE1 CRISPR monoclonal cell lines and that gRNA targeted region was amplified
using PCR. T7 endonuclease assay was performed with WT RPE1 DNA and monoclonal
cell DNA and run on an agarose gel.
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Figure 3.11. Immunofluorescence visualizing Ku70-HA in HEK293 Ku70-HA
TREX stable cells induced and uninduced with doxycycline. Ku70-HA expression
was induced with doxycycline for 24 hours. Cells were probed with DAPI (blue) and
anti-HA antibodies (green). White bars denote 200 μm.
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Next, the Ku70-HA TET-ON system was characterized. After the addition of
doxycycline, 8 hours was the shortest timepoint at which Ku70-HA was detected by
western blot and 16 hours appeared to represent the timepoint for maximum Ku70-HA
expression (Figure 3.12A). After the removal of doxycycline, it took at least seven days
for the near-complete disappearance of Ku70-HA (Figure 3.12B). Total Ku70 levels
appear to correlate to tubulin levels and were not affected by the reduction of Ku70-HA,
indicating that Ku70-HA levels do not make up a substantial proportion of total Ku70 in
the cells.
This new HEK293 TREX Ku70-HA cell line was consistently cultured in 1 µg/ml of
doxycycline to express back-up Ku70-HA and transfected with SaCas9 and TevSaCas9
containing plasmids. For these experiments, three separate gRNA targeting three different
intron-exon junctions in Ku70 (exon 6, 7, and 12) were selected. They were cloned using
golden gate into individual px458neoRSaCas9GFP and px458neoRTevSaCas9GFP plasmids.
During transfection, cells were co-transfected with either three px458neoRSaCas9GFP
constructs or three px458neoRTevSaCas9GFP, each containing one of three gRNA.
Over 60 clones were isolated from SaCas9 and TevSaCas9 transfected HEK293 TREX
Ku70-HA cells. Select clones were analysed through Western blotting for protein
analysis by graduate student, Rachel Kelly (Figure 3.13). Three potential knockout
candidates were found, Sa11, TIA, and SA. These clones showed substantially lowered
expression of both Ku70 and Ku80 when doxycycline was removed for 9 days from their
media leading to the shut off of Ku70-HA expression.
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Figure 3.12A. Western blot analyses of doxycycline-induced expression of Ku70-HA
in HEK293 Ku70-HA TREX stable cells. Whole cell extracts taken from HEK293
Ku70-HA TREX cells that were treated with doxycycline (1 µg/ml) for 0, 4, 8, 16, 24
hours. Blot was probed with, anti-HA and anti-actin antibodies. B. Western blot
analyses of repression of Ku70-HA in HEK293 Ku70-HA TREX stable cells in the
absence of doxycycline. Whole cell extracts taken from HEK293 Ku70-HA TREX cells
that were treated with doxycycline (1 µg/ml) for 24 hours. Afterwards, doxycycline was
removed and cells were harvested at different timepoints (2 – 7 days). Blot was probed
with anti-Ku70, anti-HA and anti-actin antibodies.
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Figure 3.13A. Western blot analyses of SaCas9 and TevCas9 treated HEK293 Ku70HA monoclonal cell lines. Cell harvesting and Western blotting was conducted by
graduate student, Rachel Kelly. Whole cell extracts taken from monoclonal cell lines
picked from CRISPR-transfected HEK293 Ku70-HA cells selected with G418.
Doxycycline was removed from Dox off samples for 9 days prior to harvest and lysis.
Blot was probed with anti-Ku70 antibody, anti-Ku80 antibody and anti-tubulin antibody
as the loading control. B. Western blot analyses of the same SaCas9 and TevCas9
treated HEK293 Ku70-HA monoclonal cell lines from Figure 3.13A. Cell harvesting,
and Western blotting was conducted by graduate student, Rachel Kelly. Whole cell
extracts taken from monoclonal cell lines from Figure 3.13A were run on a separate gel
to probe specifically for Ku70-HA (not endogenous Ku70). Blot was probed with antiHA antibody, anti-Ku80 antibody and anti-tubulin antibody as the loading control.
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Chapter 4

4

Discussion

4.1

Summary

The objective of this project was to create Ku70 knockouts as a tool to study Ku mutants
and to evaluate whether Ku70 is essential or not in human cells. The aim was also to
compare knockout efficiencies of two gene editing tools, CRISPR/Cas9 and
CRISPR/TevCas9 that were used to create Ku70 knockouts in HEK293 cells and RPE1
cells. We created stable cell lines with a second, inducible copy of Ku70-HA to attempt to
create conditional knockouts of Ku70 to more definitively evaluate the effect that deleting
Ku70 on human cells. We were unsuccessful in creating an inducible Ku70-HA system in
RPE1 cells, possibly due to poor transfection efficiency. In HEK293 Ku70-HA cells, we
were able to knockout Ku70, in the presence of Ku70-HA.

4.2

Knockout Attempts in WT HEK293 Cells

Experiments conducted in wild type HEK293 cells suggest that TevSpCas9 and SpCas9
were expressing and cleaving in vivo. Cleavage resistance assays performed using DNA
harvested from TevSpCas9 and SpCas9 transfected cells indicated that the nucleases were
active in HEK293 cells and genome editing was occurring. However, when monoclonal
colonies were analysed, no knockouts were found. This may have been due to many factors.
The first reason may be that too few clones were screened. Only 22 monoclonal cell lines
were analysed. The resistance bands in the digested lane on the cleavage resistance assay
were very faint compared to the band in the undigested lane, indicating that a very small
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proportion of the cells in the population underwent editing. If the gRNA targeting
efficiency was low or the plasmid transfection efficiency was low, this may have increased
the number of clones that were required to be screened to identify a Ku70 knockout.
Another reason may be that Ku70 is essential, as editing can be visualized in the cleavage
resistance assay when cells were harvested only 24 hours after selection. However, after
passaging cells in the process of culturing colonies into monoclonal cell lines, the Ku70
knockout cells may have died. Alternatively, some editing events may be isolated to the
intronic region and have no effect on the final protein product. Since the MslI restriction
site spans the intron-exon junction, cleavage resistance likely indicates that the deletion
extended into the exon. It is possible, however, that the deletion may not reach the exon
and have no effect on the Ku70 protein. The cut site for MslI extends 3 bp into the intron,
and modification in those base pairs will disrupt the enzyme cut site and produce resistance
to cleavage however, since it is located in the intron, will not affect Ku70 protein
expression.
Interestingly, it was observed that compared to the SpCas9 transfected sample, there was
2- to 3-fold more cell death in the TevSpCas9 transfected sample. This is not due to poor
TevSpCas9 transfection efficiency as live-cell imaging revealed that TevCas9 was being
transfected at higher levels compared to SpCas9. One possible explanation for this could
be that although TevSpCas9 is being successfully transfected, it may simply be more toxic
to cells than Cas9. It remains to be further examined. This could be determined by
comparing cell death between HEK293 cells transfected with control plasmids containing
SpCas9 and TevSpCas9 but missing gRNA. However, conclusions about TevSpCas9
toxicity could not be made because following antibiotic selection, these controls displayed
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complete cell death. It is unclear why cells transfected with no-gRNA control plasmids did
not survive antibiotic selection. Live-cell imaging revealed that the no-gRNA transfection
was successful however occurred at a lower efficiency than the Ku70 gRNA-containing
counterpart. Lower transfection efficiency may have led to cell death following selection.
However, further transfections are required to determine TevSpCas9 toxicity compared to
SpCas9.
Another possibility is that TevSpCas9 may be more successfully inducing deletions in the
Ku70 exon. If true, this would suggest that the successful knockout of Ku70 is lethal, and
this could explain the difference in observed cell death between TevSpCas9 and SpCas9.
This is supported by the observation that confluency differences were only in plates
transfected with TevSpCas9 and SpCas9 with gRNA, not in plates transfected without
gRNA. This would match the results of previous attempts at knocking down Ku that found
knockout resulted in cell death (39–41). The SpCas9 cells may have survived because
SpCas9 created heterogeneous indels that were largely located in the intron and do not
extend into the preceding exon. However, there was not enough evidence to fully support
this conclusion. This could be determined using Illumina sequencing of PCR-amplified
product containing the target site used for the cleavage resistance assay.
Deep sequencing could be used to determine the type and length of indels as well as
quantify the frequency of these editing events. This technique was previously used in Wolfs
et. al. (2016) to show the 33-36 bp deletion bias caused by TevSpCas9 (53). When
analysing target site DNA from SpCas9 transfected cells, a range of insertion and deletions
lengths were observed, most common being a +1 insertion event (53). It appears that +1
insertion events are one of the most common editing events caused by SpCas9 (69). In my
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experiments, editing events of a +1 insertion caused by SpCas9 targeting target site 0 would
occur exclusively in the intron in the Ku70 gene and would not affect the protein sequence
of Ku70. This may explain why less cell death was observed in SpCas9 transfected cells if
we assumed that Ku70 is essential.
We followed up these experiments with the construction of a stable cell line with a second
inducible copy of Ku70 with tetracycline-controlled transcriptional activation. If Ku70 can
be successfully knocked out in these cells, this system can be used to investigate the
lethality of a Ku70 knockout. If shutting off the expression of the second copy of Ku results
in the death of the knockout cells, this will confirm that Ku is essential in HEK293 cells.

4.3

Analysing CRISPR Clones in HEK293 Ku70-HA Stable Cells

We created a HEK293 stable polyclonal cell line with an inducible second, exogenous copy
of Ku70 controlled by a Tet-OFF promoter. Ku70-HA expression decreased in response to
tetracycline. However, we found it preferable to use doxycycline instead. While both
tetracycline and doxycycline have a half-life of approximately 24 hours in tissue culture
media, lower concentrations of doxycycline can be used to produce the same induction
effect as tetracycline used at a much higher, possibly cytotoxic level (70). Even after 7 days
of doxycycline repression, the TET-OFF system still showed some very faint bands
indicating very low levels of Ku70-HA expression on a western blot. This could be due to
leakage of the TET-OFF system or incomplete degradation of Ku70. Ku70 may require
longer than 7 days to be completely degraded.
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CRISPR transfections were repeated in HEK293 Ku70-HA stable cells. Constructs
containing SaCas9 and TevSaCas9 T2A linked to GFP were used hereafter in these
experiments in the place of SpCas9 and TevSpCas9 containing constructs. Live-cell
imaging confirmed successful transfection and expression of the nucleases in HEK293
Ku70-HA cells. Out of 40 analysed clones, 2 clones derived from SaCas9 transfected
HEK293 Ku70-HA cells, clones 22 and 27, showed significant knockdown of Ku70
expression. After genome analysis, we determined that clone 22 showed a 54 bp
heterozygous deletion while clone 27 contained a 19 bp heterozygous deletion. Both
deletion events were large enough to extend into the exon which means that the deletions
likely functioned to disrupt the splicing of Ku70. Interestingly, these mutations were
heterozygous. It has been observed that heterozygous Ku70 HTC116 knockouts are
haploinsufficient for Ku70 as they have slower growth rate, higher sensitivity to ionizing
radiation, and shortened telomeres compared to wild type HTC116 (68). Similar
phenotypes were also observed in heterozygous Ku80 knockouts (40, 71). Clones 22 and
27 were not tested for telomere length or ionizing radiation sensitivity, however, they did
not display the slower growth rate phenotype.
It is important to note that these knockout experiments were conducted in HEK293 Ku70HA cells which contained a backup copy of Ku70-HA. This extra copy could have allowed
these heterozygous knockouts to overcome the haploinsufficiency. However, there was not
enough data to conclude Ku70 haploinsufficiency in these clones. Unfortunately, due to
fungal contamination, these clones were not analysed after doxycycline release to observe
their behaviour and Ku70 expression levels after shutting off Ku70-HA expression.
HEK293 are tetraploid for chromosome 22, the chromosome that carries the Ku70 gene
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(72). This may be another possible reason why our heterozygous knockout clones did not
show a growth rate defect.

4.4

Ku Levels in Human Cells

RPE1 cells were found to have significantly lower Ku70 expression compared to HEK293
cells. This is consistent with each cell line’s respective gene copy number. Many common
immortalized cell lines used in the lab show high levels of genomic instability and are
polyploid for chromosome 22, such as HeLa and HEK293 cell lines (73, 74). In normal
cells, Ku is most well-known for its function in NHEJ, however, it has also been implicated
in V(D)J recombination, telomere conservation, DNA replication, cell cycle control and
anti-apoptosis (17, 71, 72). Interestingly, Ku upregulation has been linked to the
progression of certain tumour types, such as chronic lymphocytic leukemia, bladder cancer
and breast cancer (75, 76). This may support our assumption that a near-diploid cell line
such as RPE1 cells may be more representative of ‘normal’ human cells compared to
polyploid cell lines such as HEK293 and cancer cell lines such as HTC116. Higher levels
of Ku in cells more prone to genomic instability may indicate a higher dependence on Ku
and its role in various cellular processes. Thus, knockout of Ku in these cells may only
produce cell line specific results and may not be generalized to ‘normal’ human cells. This
remains to be further explored by comparing Ku levels and attempting heterozygous and
homozygous knockouts across various (primary, immortalized, stable diploid and
cancerous) human cell lines.
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4.5

CRISPR in RPE1 Cells

CRISPR experiments conducted in wild type RPE1 cells yielded interesting results. As
seen in HEK293 Ku70-HA cells, live-cell imaging revealed that SaCas9 and TevSaCas9
were being transfected and expressed in RPE1 cells. Similar to observations made for
transfections conducted in wild type HEK293 cells, RPE1 cells transfected with gRNA
show more death in comparison to cells transfected with no-gRNA as control. This
supports the suggestion that Ku70 knockouts are lethal. This hypothesis is also consistent
with previously seen results observed in wild type HEK293 cells where TevSpCas9 +
gRNA transfected samples showed higher cell death compared to SpCas9 + gRNA.
TevSpCas9 may have been creating Ku70 knockouts more efficiently and killing more
cells compared to SaCas9.
CRISPR-transfected RPE1 population before antibiotic selection were genomically
analysed using TIDE to screen for editing events in the population after transfection. Very
low levels of editing were found in both SaCas9 and TevSaCas9 samples. Interestingly,
the most common editing event in the SaCas9 sample was a 1 bp insertion. This was
expected and consistent with the fact that a 1 bp insertion is the most common indel created
by Cas9 (69, 77). The TevSaCas9 sample revealed the most common editing event to be
36 base pair deletion. This was expected as it corresponds to the length of bases between
the Tev cut site and the SaCas9 cut site present in the TevSaCas9 target site. This provided
strong support that SaCas9 and TevSaCas9 were functional in RPE1 cells and at the Ku70
gRNA targeted site, however, this occurred at a very low level. Out of over 60 clones
screened, no knockouts or knockout candidates were found. This was not surprising as
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Ku70 appears to be a difficult gene to target for gene editing. Fattah et. al. (2008) found a
success rate of 0.69% when attempting to target the Ku70 gene in HCT116 cells (68). They
were only able to obtain 3 Ku70 heterozygous knockouts out of the screened 437 antibioticresistant clones. Interestingly, retargeting the remaining Ku70 allele in heterozygous
knockouts resulted in a 6-fold increase in gene targeting frequency. From their results, it
appears reduced Ku70 expression levels may increase the frequency of gene targeting. It is
important to note that gene editing was accomplished through the use of recombinant
adeno-associated virus which relies on homologous recombination (68). This differs from
the method used in this project, SaCas9, which relies on NHEJ without the presence of a
repair complex.
The answer may simply lie in the screening of more clones to acquire an RPE1 Ku70
knockout. A study in Nature Medicine reported that genome editing using CRISPR may
be less efficient in human cells with a wild type p53 response such as RPE1 cells (78).
Their results suggest in p53-proficient cells, Cas9 induced DSBs to activate p53, leading
to a growth arrest. This explains the relative difficulty of editing normal, untransformed
human cells.

4.6

Attempting to Create Ku70-HA Stable Cells in RPE1 Cells

Many unsuccessful attempts were made to recreate the inducible Ku70-HA system in RPE1
cells using many different transfection methods (Lipofectamine 3000, jetPRIME, Mirus
Bio TransIT-X2, and calcium phosphate). Though all methods were able to successfully
transiently transfect plasmid carrying tetracycline-controlled Ku70-HA into RPE1 cells,
none resulted in stable integration after selection. It is unclear at this point what the problem
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may be. Low RPE1 transfection efficiency may require more colonies to be screened when
creating a stable cell line. Different methods of transfections should be tested to increase
transfection efficiency. Fugene (79), liposome-mediated transfection method and Lonza
Nucleofector, electroporation method, (80) have been successful in RPE1 cells.

4.7

CRISPR Clones in TREX HEK293 Ku70-HA Stable Cells

In the second attempt to obtain Ku70 knockout HEK293 cells, transfections were
performed with 3 gRNAs, simultaneously targeting exon 6, 7, and 12, whereas previous
experiments only used one gRNA. Over 60 monoclonal cell lines were screened with
doxycycline and without doxycycline (for 8 days). Clones Sa11, SA (SaCas9 clones) and
TIA (TevCas9 clone) cultured without doxycycline showed very low to no Ku70
expression. Ku80 showed the same result. This was expected as Ku70 and Ku80 are
obligate heterodimers, meaning that the knockout of either subunit in Ku results in a drop
in expression of the other to negligible levels. Subunit dimerization likely has a stabilizing
effect on both subunits (18, 19). The absence of Ku80 further supports the conclusion that
these clones are indeed Ku70 knockouts.
Efficiencies of SaCas9 compared to TevSaCas9 can be determined after analyses of 50+
clones that are yet to be screened. When comparing the number of clones, SaCas9 provided
3 - 4 times more clones compared to TevSaCas9 transfections. Part of this discrepancy may
be explained by the fact that SaCas9 is about 2 kb smaller than TevCas9 and smaller
plasmids usually have a higher transfection efficiency (81).
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4.8

Future Perspective

In future studies, these clones will have to be analysed by sequencing to determine which
gRNA caused an indel that disrupted the splice site of Ku70. It would be interesting to see
if more than one gRNA target site showed editing. Doxycycline released cells need to be
observed for cell death to determine whether Ku70 is essential in HEK293 cells. Our
conditional knockout can also be used to study the stability of Ku70 in HEK293 cells by
measuring the length of time required for complete Ku70 depletion after doxycycline
release. Many other factors can also be observed such as any phenotype changes observed
in the knockouts after doxycycline release and changes in telomere length of the knockouts
once doxycycline is removed. Ku functions by promoting the association of telomerase
with telomeres (30–32). It has been speculated that the essential function of Ku is due to
its function in telomere protections rather than its role in NHEJ. Loss of Ku in human cells
has previously been associated with dramatic telomere loss (82, 83). Future experiments
will reveal if our conditional knockout will display phenotypes that are in concordance
with previous findings.
RPE1 cells were immortalized through the introduction of telomerase into retinal
pigmentation cells. Thus, they display genomic stability, growth characteristics, and gene
expression patterns that mimic young normal cells (45). HEK293 cells show greater
polyploidy and genome instability that suggests a greater reliance on DNA repair
mechanisms, namely NHEJ which is the major DSB repair process in mammals (23, 44).
This could be a confounding variable while trying to generalize conclusions about Ku
gathered from HEK293 cells to all human cells. Although attempts to create an RPE1
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conditional Ku70 knockout were not successful in this project, that goal should be further
pursued as diploid RPE1 cells would be more representative of ‘normal’ human cells
compared to polyploid HEK293 cells.
As many cellular functions of Ku are yet not well characterized, using an enzyme-catalyzed
proximity system such as proximity-dependent biotin identification (BioID) has been used
to reveal less known and yet to be discovered transient interactors of Ku (84). Mutant forms
of Ku70 or BioID-tagged Ku70 can be stably integrated into these knockout cell lines to
further study the function of Ku70 without interference from highly expressed, endogenous
Ku70. Further studies should be conducted to compare the interactome of Ku in humans
with mice and other organisms where Ku has been successfully knocked out to understand
why Ku appears to be essential in humans. Advances in BioID have produced TurboID,
which can label interactors in matters of minutes as compared to 18 hours required by
BioID (85, 86). This could be paired with mass spectrometry to capture a snapshot of the
Ku interactome under specific cellular conditions, such as during the repair of DSBs to
better understand Ku in the context of DNA repair.
To improve gene editing efficiencies of either SaCas9 or TevSaCas9, the method of
introducing TevSaCas9 and SaCas9 may be switched from plasmid transfection to using
electroporation to directly deliver TevCas9 and Cas9 complexed with synthetic gRNA into
cells. Using the protein version of Cas9 has been shown to increase cleavage compared to
Cas9 delivered into cells on a plasmid (87). The process of selecting monoclonal cell lines
can also be optimized by using fluorescence activated cell sorting (FACS) instead of
antibiotic selection. FACS is comparatively faster (88) and less likely to produce false
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positives as the nuclease and GFP are under the same promoter in our plasmid constructs
but the antibiotic resistance marker is controlled by its own promoter.

4.9

Conclusion

The knockout strategy employed in this work can be generalized to knockout other highly
expressed genes that may have multiple pseudogenes present in the genome. Pseudogenes
do not contain exons; thus, introns can be targeted near an intron-exon junction. With
TevCas9, it is possible to get cleavage in the exon itself, while only targeting the intron.
With Cas9, this is much less likely and dependent on error-prone exonucleolytic processing
to create deletions large enough to extend into the exon, demonstrating the versatility of
using TevCas9 in addressing more challenging knockout targets.
Ku70 plays an important role in the NHEJ repair pathway. Ku70 knockout has already been
achieved in mouse cells and used to link Ku-deficiency to increased cancer incidence and
early onset of aging (17). However, studying Ku is difficult in human cells without a Ku70
knockout human cell line. We were able to create a conditional knockout of Ku70. This
cell line can be used to investigate if Ku is essential in HEK293 cells. If found to be
essential, this would be consistent with previous findings that indicated that knocking out
Ku70 is lethal in other human cell lines and the lack of a single patient with a Ku70 or
Ku80 genetic disease related mutation (17, 39, 42, 68). The conditional Ku70 knockout
created in this project can serve as the basis for studies further investigating other cellular
roles of Ku outside of NHEJ, such as telomerase maintenance, and why Ku only appears
to be indispensable for human cell viability.
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